NEWS & EVENTS

December 4, 2023

OXFORD BIOMEDICA SIGNS AGREEMENT TO ACQUIRE ABL EUROPE FROM INSTITUT MERIEUX

Read more


October 24, 2023

HOW TO CHOOSE THE RIGHT CDMO PARTNER

Read more


October 19, 2023

KEY CMC CONSIDERATIONS FOR THE DEVELOPMENT OF YOUR VIRUS / VIRAL-VECTOR PROGRAMS

Read more


October 5, 2023

UNLOCKING SUCCESS IN GENE THERAPIES: THE CRUCIAL ROLE OF QTPP AND FINDING THE RIGHT PARTNER TO DEPLOY THE QBD APPROACH

Read more


September 21, 2023

OXFORD BIOMEDICA AND INSTITUT MERIEUX ENTER INTO EXCLUSIVE NEGOTIATIONS FOR THE PROPOSED ACQUISITION OF ABL EUROPE

Read more


September 18, 2023

ASEPTIC PROCESS OF VIRAL VECTOR-BASED VACCINES – KEY ASPECTS TO CONSIDER BEFORE CLINICAL MANUFACTURING

Read more


August 29, 2023

PROCESS CHARACTERIZATION OF VIRAL VECTORS: APPROACH IN CDMO CONTEXT

Read more